Monensin (sodium)

Monensin (Monensin A) sodium, an orally active antibiotic, is an ionophore that mediates Na+/H+ exchange. Monensin sodium is a potent Wnt signaling inhibitor. Monensin sodium causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin sodium can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects[1][2][3][4].

Product Specifications

CAS Number

[22373-78-0]

Product Name Alternative

Monensin A (sodium)

UNSPSC

12352005

Hazard Statement

H300

Target

Antibiotic; Apoptosis; Bacterial; Fungal; Na+/H+ Exchanger (NHE) ; Parasite; Wnt

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Membrane Transporter/Ion Channel; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/monensin-sodium.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 20 mg/mL (ultrasonic)

Smiles

OC[C@@]1(O)[C@H](C)C[C@H](C)[C@]([C@@]2(O[C@]([C@@]3(CC[C@@]([C@]4(O[C@@]5(C[C@H](O)[C@@H](C)[C@@]([H])([C@H]([C@@H](OC)[C@H](C)C(O[Na])=O)C)O5)CC4)C)([H])O3)CC)([H])[C@@H](C)C2)[H])([H])O1

Molecular Formula

C36H61NaO11

Molecular Weight

692.85

Precautions

H300

References & Citations

[1]Dayekh K, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther. 2014 Nov;13 (11) :2559-71.|[2]Tumova L, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther. 2014 Apr;13 (4) :812-22.|[3]Youhua Huang, et al. Autophagy Participates in Lysosomal Vacuolation-Mediated Cell Death in RGNNV-Infected Cells. Front Microbiol. 2020 Apr 30:11:790. |[4]Ariel Savina, et al. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic. 2005 Feb;6 (2) :131-43.